Table 1.

PACE: efficacy among patients with AP-CML and BP-CML (adapted from [6, 10])

	AP-CML (n = 83)	BP-CML (n = 62)
6-month response; BP-CML 1-year response; AP-CML 5-year response; AP/BP-CML PFS OS	MHR: 55%, MCyR: 39%, CCyR: 24%, MMR: 16% MHR: 61%, MCyR: 49%, CCyR: 31%, MMR: 22% 55% (1-year), 22% (5-year) 84% (1-year), 49% (5-year)	MHR: 31%, MCyR: 23%, CCyR: 18% MHR: 31%, MCyR: 23%, CCyR: 18%, MMR: 13% 19% (1-year), 3.7 mo (5-year) 29% (1-year), 9% (3-year)

CCyR, complete cytogenetic response; MCyR, major cytogenetic response; MHR, major hematologic response; MMR major molecular response; OS, overall survival; PFS, progression-free survival; BP-CML, blast phase chronic myeloid leukemia; AP-CML, accelerated phase; PACE, Ph+ ALL and CML Evaluation.